ArticleJournal of experimental & clinical cancer research : CR2026
Alkylating agents activate an SLFN11-dependent vulnerability that confers PARP-1 inhibitor sensitivity in kidney cancer.
Chenliang Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.